Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.

Download All Current Trials

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • PCA001 Vaccitech

    A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immnotherapeutic in Men wiht Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer

    Cancer Type: PROSTATE

    Phase: 1

  • CP-MGD019-02:

    A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxe or Docetaxe Alone in Participants with Metatatic Castration-Resistant Prostate Cancer

    Cancer Type: PROSTATE

    Lines of Therapy: 2

    Phase: 2

  • XB002-101

    A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors (JEWEL-101)

    Cancer Type: HEAD AND NECK, Pancreatic, Lung NSCLC, Cervical, HR+ Breast

    Lines of Therapy: 3, 2

    Phase: 1

    View Details on ClinicalTrials.gov

  • D8535C00001, CAMBRIA 2

    A Phase 3, randomized study to assess the efficacy and safety of Camizestrant (AZD9833) vs standard endocrine therapy as adjuvant treatment for ER+/Her2- Early Breast Cancer and an Intermedicate-high or High risk recurrance who have completed definitive locoregional treatment and have no evidence of disease.

    Cancer Type: BREAST

    Lines of Therapy: 1

    Biomarkers: Her2-, ER+

    Phase: 3

  • Tempus: Gemini TP-CA-002 (NSCLC - Surveillance)

    Tempus NSCLC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With NSCLC Using NGS Assays

    Cancer Type: Lung NSCLC

    Phase: Observational

    View Details on ClinicalTrials.gov

  • SGNTUC-028

    A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

    Cancer Type: BREAST

    Lines of Therapy: 3

    Biomarkers: HR, HER2+

    Phase: 3

    View Details on ClinicalTrials.gov

  • TIG-006, iTeos

    Multi-center, open label, phase 1/2 study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

    Cancer Type: Solid tumor

    Phase: 2

    View Details on ClinicalTrials.gov

  • RYZ101-101

    Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)

    Cancer Type: Lung SCLC

    Lines of Therapy: 1

    Biomarkers: SSTR+

    Phase: 1

    View Details on ClinicalTrials.gov

  • Tempus Priority

    Tempus Priority Study: A Pan-tumor Observational Study

    Phase: Observational

    View Details on ClinicalTrials.gov

  • Tempus: Gemini TP-CA-004 (CRC - Surveillance)

    Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

    Cancer Type: Colorectal

    Phase: Observational

    View Details on ClinicalTrials.gov

Call   •   Fax   •   Convenient Locations

#caringforthegoodlife

© 2023 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content